Speciality: All Speciality
Description:
A warm welcome to all the medical professionals in this interesting session on the benefits of influenza vaccination in the high-risk populations of diabetes and COPD patients.
Influenza is responsible for multiple deaths and about 20 to 30% of the deaths occurring annually are observed in children depicting the poor condition of controlling influenza in children. The virus is present globally but is not that powerful to create an epidemic.
Among people with diabetes and chronic lung disease like COPD influenza causes severe impacts and flu vaccination has been shown to be associated with reduced hospitalizations from a worsening of their chronic condition. Flu vaccinations can shorten the length of hospital stay due to flu, reduce the risk of ICU admission from flu, and also helps in reducing the risk of death from flu.
Therefore, get an overall knowledge regarding the benefits of influenza vaccination in high-risk populations of diabetes and COPD patients. Listen to the webinar, grab the knowledge that is shared, and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Beyond What Is Visible in Myelofibrosis?
2.
FDA approves rivanetin as the first-line treatment for lung cancer.
3.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
4.
New First-Line Option for Advanced ALK-Positive Lung Cancer
5.
Certain surgical gestures during prostate removal linked to better sexual function recovery
1.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
2.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
3.
Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review
4.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
5.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation